![new-post-epigenetic-le](https://bridgemedicines.com/wp-content/uploads/2020/11/new-post-epigenetic-le.jpg)
Bridge Medicines Signs Agreement with The Rockefeller University for Further Preclinical Development of Breslow Lab Assets
NEW YORK, NEW YORK – September 21, 2020
Bridge Medicines and The Rockefeller University today announced an exclusive license agreement to further develop a series of small molecule inhibitors of activated Factor XII (FXIIa) discovered in the laboratory of Jan L. Breslow, M.D.